Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03510702
Other study ID # H1510580113419
Secondary ID
Status Recruiting
Phase
First received April 1, 2018
Last updated April 26, 2018
Start date September 15, 2017
Est. completion date July 2019

Study information

Verified date April 2018
Source University of Valencia
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Epigenetics has produced a high impact in biomedical research and is providing new biomarkers for the diagnosis and prognosis of diseases. In addition, epigenetics is also contributing to analyze the molecular causes underlying diseases, even so periodontal diseases as it has been recently reviewed. In this regard, changes in the methylation of genes codifying for pro-inflammatory and anti-inflammatory cytokines has been previously reported. miRNAs are very promising biomolecules to be used as biomarkers because miRNAs act as signaling molecules and participate in many biological processes, such as cellular development, differentiation, and apoptosis. The high stability of circulating miRNAs in the RNase-rich environment of the bloodstream and also in different biospecimens used in clinical routine, make these biomolecules an optimal source of candidate biomarkers. In fact, miRNAs have demonstrated their value as dynamic biomarkers in a wide variety of human diseases. Therefore, miRNAs can be used for the monitoring of periodontal disease.

The objective of this research is to analyze the levels of bone remodeling RANKL / OPG biomolecular markers, and the epigenetic regulation of these proteins to identify promising biomarkers of periodontal disease.

Material and Methods. Levels of RANKL and OPG will be measured in the gingival crevicular fluid (GCF) to assess the state of bone. These samples will be sent to the lab for quantification by ELISA method.

Furthermore, new epigenetic biomarkers based on the identification of high stable microRNAs will be identified by qRT-PCR in GCF as feasible tools for diagnosis and monitoring of wide range of disease, including periodontal disease.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date July 2019
Est. primary completion date July 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 60 Years
Eligibility Inclusion Criteria:

Group of periodontal patients:

1. Clinical criteria: at least 3 locations in unirradicular teeth with PD 6 mm. 3 samples will be taken from each of these 3 locations (9 total samples). Third molars are not included in the study.

2. Patients not treated periodontally.

3. 30-60 years.

Periodontally healthy group:

1. Absence of clinical and radiographical periodontal pathology.

Exclusion Criteria:

- Group of periodontal patients:

1. Aggressive Periodontal Disease (Armitage, 1999).

2. Patients with controlled periodontal disease with plaque and gingival indexes =20%.

3. Patients with systemic diseases or taking medications that alter bone metabolism (Osteoporosis, arthritis, hormonal treatment, bisphosphonates, anti-inflammatory, immunosuppressants, etc ...).

4. Patients with antibiotic, anti-inflammatory or contraceptive treatment in the previous 3 months or taking antiaggregants in the last 7 days before taking the sample.

5. Smokers (> 10 cig. /day).

6. Pregnant or breast-feeding.

Periodontally healthy group:

1. Patients with systemic diseases or taking medications that alter bone metabolism (Osteoporosis, arthritis, hormonal treatment, bisphosphonates, anti-inflammatory, immunosuppressant...).

2. Patients with antibiotic, anti-inflammatory or contraceptive treatment in the previous 3 months or taking antiaggregants in the last 7 days before taking the sample.

3. Smokers (> 10 cig/day).

4. Pregnant or breast-feeding.

Study Design


Intervention

Diagnostic Test:
Levels of epigenetic biomarkers present in the gingival fluid and its possible relationship with bone metabolism.
Once the anamnesis has been done, all the records corresponding to the Gingival Index and Plaque Index, in both groups are taken. Subsequently, samples of gingival crevicular fluid are taken for the screening of epigenetic biomarkers.

Locations

Country Name City State
Spain Ana Fuenmayor Garcés Valencia

Sponsors (1)

Lead Sponsor Collaborator
University of Valencia

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary microRNA in gingival crevicular fluid (physiological parameter). Insert the Perio PaperĀ® tip in gingival sulcus until resistance is felt and leave it for 30 seconds. 2 years.
Secondary Probing depth. Probing depth will be measured in six sites (disto-buccal, mid-buccal, mesio-buccal, disto-palatal, mid-palatal and mesio- palatal) of every teeth with a Williams Probe PQ-OW 208 396. This probe is used by gently hanging pressure into a pocket measuring 20 grams in weight. 2 years.
Secondary Bleeding on probing. Full mouth bleeding score (FMBS) will be calculated based on scores of 0 (no bleeding) or 1 (bleeding) after probing for PD. The usual thing to do is to measure at 4 points for each tooth but we have modified the index and we valorate them at 6 points. (disto-buccal, mid-buccal, mesio-buccal, disto-palatal, mid-palatal and mesio- palatal). 2 years.
Secondary Clinical recession. Clinical recession will be measured in the same six sites as before between the Amelocemental junction and the gingival margin. 2 years.
Secondary Plaque score of Silness y löe: (1964) The Plaque will be scored as follows:
Score 0 = No plaque
Score 1 = A film of plaque adhering to the free gingival margin and adjacent area of the tooth. The plaque may be seen in situ only after application of disclosing solution or by using the probe on the tooth surface.
Score 2 = Moderate accumulation of soft deposits within the gingival pocket, or on the tooth and gingival margin, which can be seen with the naked eye.
Score 3 = Abundance of soft matter within the gingival pocket and/or on the tooth and gingival margin.
The usual thing to do is to evaluate at 4 points for each tooth but we have modified the index and we will evaluate at 6 points. (disto-buccal, mid-buccal, mesio-buccal, disto-palatal, mid-palatal and mesio- palatal)
2 years.
Secondary Dental movility of Mïller 1950 Class I
Up to 1 mm of movement in a horizontal direction.
Class II Greater than 1 mm of movement in a horizontal direction. Class III
Excessive horizontal movement and vertical movement.
2 years.
Secondary Furcation affection. Class I:
The level of bone loss allows for the insertion of the periodontal Nabers probe into the concavity of the root trunk. Furcation defect is less than 3 mm is depth.
Class II The level of bone loss allows for the insertion of a periodontal probe into the furcation area between the roots. Furcation defect is at least 3 mm in depth (and thus, in general, surpassing half of the buccolingual thickness of the tooth) but not through-and-through (i.e. there is still some interradicular bone attached to the angle of the furcation.
15
Class III The level of bone loss allows for "through and through" access of the furcation area. Buccal to lingual on lower molars. Buccal to mesio-palatal and disto-palatal on upper molars. Furcation defect encompassing the entire width of the tooth so that no bone is attached to the angle of the furcation.
2 years.
See also
  Status Clinical Trial Phase
Completed NCT04712630 - Non-Incised Papillae Surgical Approach (NIPSA) With and Without Graft N/A
Recruiting NCT03997552 - NIPSA Versus Marginal Approach by Palatal Incision and MIST in Periodontal Regeneration N/A
Completed NCT04478864 - Knowledge, Practice and State of Periodontal Health
Completed NCT03507868 - YKL-40 and IL-6 Levels in Periodontal Disease
Completed NCT05720481 - Impact of Periodontal Treatment on Growth Differentiation Factor-15 Levels N/A
Recruiting NCT06052150 - Oral Health In Cirrhosis of the Liver (ORACLE)
Recruiting NCT06025955 - Evaluation of Outcomes of Minimally Invasive Non- Surgical Versus Surgical Therapy in Furcation Involvement. N/A
Completed NCT05631600 - Manuka Honey as an Adjunct to Non-surgical Periodontal Therapy: Clinical Study Phase 2/Phase 3
Active, not recruiting NCT05068778 - Development of an AI App to Improve Compliance in Periodontal Maintenance Patients
Not yet recruiting NCT05178563 - Mechanisms of Acute Inflammation Following Periodontal Treatment N/A
Recruiting NCT06086821 - Clinical Relevance of Different Time of Periodontal Re-evaluation N/A
Recruiting NCT06224699 - Toothpaste With Sodium Carbonate in Patients With Gingivitis N/A
Not yet recruiting NCT05721313 - Vital Root Amputation in Molars With Advanced Periodontal Furcation Involvement: a Preliminary Study N/A
Completed NCT06306937 - Serum Levels of Vitamin D and IL8 in Patients With Periodontitis
Completed NCT06040944 - Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients
Recruiting NCT04669717 - Antibiotics as Adjuncts to Periodontal Therapy:Pharmacokinetic Considerations and Dosing Strategies Phase 4
Completed NCT05576142 - Oral Findings in Pediatric Patients With Allergic Rhinitis and/or Asthma
Completed NCT03694496 - The Effectiveness of an Oral Health Education Programme of Adolescents in Hong Kong N/A
Not yet recruiting NCT03588507 - Clinical and Radiographic Evaluation of PPF With or Without NCHA Bone in Treatment of Intrabony Defects N/A
Completed NCT04017078 - Assessment of Carotid Artery Calcifications